Towards Clinical Translation of CD8

Samiksha Wasnik, David J Baylink, Jianmei Leavenworth, Chenfan Liu, Hongzheng Bi, Xiaolei Tang

Open access · goldAbstract readReview

In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.1field-weighted citation impact, top 53% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Advances in the Study of CD8+ Regulatory T Cells.Critical reviews in immunology · 2019
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Samiksha WasnikDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, CA 92354, USA. swasnik@llu.edu.

David J BaylinkDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, CA 92354, USA. dbaylink@llu.edu.

Jianmei LeavenworthDepartment of Neurosurgery, the University of Alabama at Birmingham, Birmingham, AL 35294, USA. jleavenworth@uabmc.edu.

Chenfan LiuDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, CA 92354, USA. bpflcf@outlook.com.

Hongzheng BiDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, CA 92354, USA. bhz66@sina.com.cn.

Xiaolei TangDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, CA 92354, USA. xtang25@hotmail.com.ORCID 0000-0003-1492-9622

Loma Linda University · USLong Island University · USUniversity of Alabama at Birmingham · US

Funding

Loma Linda University 681205-2967National Multiple Sclerosis Society PP1685

6 · The paper itself

Abstract

In central lymphoid tissues, mature lymphocytes are generated and pathogenic autoreactive lymphocytes are deleted. However, it is currently known that a significant number of potentially pathogenic autoreactive lymphocytes escape the deletion and populate peripheral lymphoid tissues. Therefore, peripheral mechanisms are present to prevent these potentially pathogenic autoreactive lymphocytes from harming one's own tissues. One such mechanism is dictated by regulatory T (Treg) cells. So far, the most extensively studied Treg cells are CD4

Indexed as

Translational Research, BiomedicalAnimalsCD8-Positive T-LymphocytesEpitopesHistocompatibility Antigens Class IHumansImmune System DiseasesImmunomodulationPeptidesT-Lymphocytes, RegulatoryVaccinationEpitopesHistocompatibility Antigens Class IPeptidesQ surface antigensand vaccinationCD8+ Treg cellsepitopesHLA-Enon-classical major histocompatibility complex Ib moleculesQa-1

Identifiers

PMID31569411

DOI10.3390/ijms20194829

PMCPMC6801908

OpenAlexW2975149623

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.